The role of primary tumour resection (PTR) in metastatic small intestinal (SiNETs) and pancreatic neuroendocrine tumours (PanNETs) remains debated. While retrospective studies suggest improved surviv...

Background Grade 1/2 PanNETs are mostly managed similarly, typically without any adjunct treatment with the belief that their overall metastasis rate is low. In oncology literature, Ki67-index of 10% ...

Molecular studies have shown ALT to be an important prognostic biomarker of shorter relapse-free survival (RFS) for patients with pancreatic neuroendo…

Pancreatic neuroendocrine tumours (PanNETs) are a rare heterogeneous group of neoplasms that arise f

Potiri et al. uncover how the splicing factor SRRM3 drives tumor progression in pancreatic neuroendocrine tumors (PanNETs) via neural microexon inclusion. Aberrant splicing disrupts insulin secretion and calcium signaling, revealing a novel link between neuroendocrine dysfunction and cancer. Therapeutic redirection using splice-switching ASOs can effectively impair tumor growth in preclinical models.

Everolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The …

Alkylating agent-based chemotherapy is one of the main treatment options for patients with metastatic pancreatic neuroendocrine tumors (PanNETs).However, it favors the acquisition of a hypermutator ph...

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring because their cancer is more likely to recur.

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring bec...

A predictive model effectively identifies patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs) at high risk for early recurrence (ER). Developed from a cohort of 496 patients, the model leverages preoperative clinical, pathological, and imaging variables, achieving an AUC of 0.91 in training and 0.84 in validation. Neoplastic venous thrombosis emerged as the strongest recurrence predictor,

Refining the Prognostic Blueprint for Pancreatic Neuroendocrine Tumors A recent study published in the Annals of Surgical Oncology focuses on refining prognostic stratification for Grade 2 pancreatic neuroendocrine tumors (PanNETs). This research is critical for advancing personalized oncology, as accurate risk assessment directly informs treatment intensity, surveillance schedules, and patient counseling. The findings contribute to the evolving landscape of tumor classification, moving beyond traditional grading to incorporate novel molecular or clinicopathologic factors that better predict clinical behavior and outcomes in this heterogeneous disease.

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring because their cancer is more likely to recur.

The CD93/IGFBP7 axis is enriched in pancreatic neuroendocrine tumors (PanNETs) and blockade of this pathway with monoclonal antibodies normalizes tumor vasculature to inhibit cancer progression and metastasis. In addition, CD93 blockade treats advanced PanNETs that are otherwise unresponsive to sunitinib by inducing hypoxia and preventing the induction of proangiogenic factors.

Pancreatic neuroendocrine tumours (PanNETs) are a rare heterogeneous group of neoplasms that arise f

Streptozotocin (STZ), first described in 1960 as a nitrosourea antibiotic isolated from Streptomyces achromogenes, was initially investigated for its antimicrobial activity. It was subsequently identified as a targeted cytotoxin for pancreatic β-cells due to its high affinity for the glucose transporter type 2 (GLUT2). This biological selectivity, combined with its DNA-alkylating properties, supported its early repurposing as an antineoplastic agent for pancreatic neuroendocrine tumours (panNETs) [1].

The role of primary tumour resection (PTR) in metastatic small intestinal (SiNETs) and pancreatic neuroendocrine tumours (PanNETs) remains debated. While retrospective studies suggest improved survival and possible reduction of local complications, the evidence is limited by heterogeneity, selection …